Titre du document / Document title

Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression

Auteur(s) / Author(s)

MAES M. ^{(1 2)} ; VANDOOLAEGHE E. ⁽¹⁾ ; DESNYDER R. ⁽¹⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Clinical Research Center Mental Health, University Department of Psychiatry, AZ Stuivenberg, 267 Lange Beeldekensstraat, 2060 Antwerp, BELGIQUE
⁽²⁾ Department of Psychiatry, Vanderbilt University, Nashville, TN, ETATS-UNIS

Résumé / Abstract

Fluoxetine, a selective serotonin (5-HT) reuptake inhibitor (SSRI), and trazodone, a heterocyclic antidepressant, are effective in the treatment of major depression and treatment resistant depression (TRD). Chronic treatment with both drugs causes increases in extracellular 5-HT through 5-HT reuptake inhibition and desensitization of inhibitory 5-HT_1A autoreceptors. It has been shown that pindolol, a serotonin (5-HT)_1A-receptor antagonist, may shorten the latency of onset of SSRIs in depression. The aim of the present study was to examine whether pindolol may increase the efficacy of a subtherapeutical dosage of trazodone in the treatment of major depression and TRD, defined according to the Thase and Rush criteria (1995). Thirty-three major depressed inpatients of whom 26 with TRD participated in this study. Ten days after hospitalization, treatment with trazodone 100 mg/day was started. After I week trazodone treatment, patients were randomized - using a double blind placebo controlled design - to receive trazodone 100 mg/day + placebo; trazodone 100 mg/day + pindolol 7.5 mg/day; or trazodone 100 mg/day + fluoxetine 20 mg/day and treated during 4 weeks. The 17-item Hamilton Depression Rating Scale (HDRS) was used as outcome measure. It was found that trazodone + pindolol was as effective as trazodone + fluoxetine in the treatment of major depression and TRD and significantly more effective than trazodone + placebo. Using an outcome measure of 50%. reduction in the HDRS, we found that 72.5% of the depressed patients treated with trazodone + pindolol and 75% of depressed patients treated with trazodone + fluoxetine showed a clinically significant response compared with 20.0% of trazodone + placebo-treated patients.

Revue / Journal Title

Journal of affective disorders   ISSN 0165-0327   CODEN JADID7 

Source / Source

1996, vol. 41, n^o3, pp. 201-210 (1 p.1/2)

Langue / Language

Anglais

Editeur / Publisher

Elsevier, Amsterdam, PAYS-BAS  (1979) (Revue)

Mots-clés anglais / English Keywords

Depression ; Mood disorder ; Chemotherapy ; Trazodone ; Antidepressant agent ; Psychotropic ; Drug combination ; Fluoxetine ; Reuptake inhibitor ; Serotonin ; Pindolol ; Antagonist ; 5-HT1A receptor ; Comparative study ; Human ;

Mots-clés français / French Keywords

Etat dépressif ; Trouble humeur ; Chimiothérapie ; Trazodone ; Antidépresseur ; Psychotrope ; Association médicamenteuse ; Fluoxétine ; Inhibiteur recapture ; Sérotonine ; Pindolol ; Antagoniste ; Récepteur sérotoninergique 5-HT1A ; Etude comparative ; Homme ;

Mots-clés espagnols / Spanish Keywords

Estado depresivo ; Trastorno humor ; Quimioterapia ; Trazodona ; Antidepresor ; Psicotropo ; Asociación medicamentosa ; Fluoxetina ; Inhibidor recaptura ; Serotonina ; Pindolol ; Antagonista ; Receptor serotoninérgico 5-HT1A ; Estudio comparativo ; Hombre ;

Localisation / Location

INIST-CNRS, Cote INIST : 18006, 35400006127667.0060